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FACTORS INVOLVED IN PARENTAL DECISION-MAKING WHEN 
PROVIDING CONSENT ON BEHALF OF EXTREMELY PRETERM INFANTS 
IN THE PENUT TRIAL 
 
TIGLATH ZIYEH 
ABSTRACT 
 
Background: Neurodevelopment and growth are primary concerns when neonates are 
born extremely premature (between 23 and 28 weeks gestation). The focus of the PENUT 
Trial is to administer erythropoietin (Epo) to extremely preterm infants and to study the 
potential neuroprotective effects of Epo. The PENUT ethics survey was designed to 
provide study investigators with parental feedback regarding the consent process for the 
PENUT Trial and to improve the consent process for future research trials. 
 
Objectives: The objectives of this research thesis are to learn (1) what factors are 
important to parents who are approached for informed consent to include their infants in a 
research study and (2) how parents may be influenced by demographic and social factors. 
The hypothesis is that parents approached prenatally may be more likely to consider 
enrolling their infants into the PENUT Trial. 
 
Methods: All parents approached to enroll their eligible infants into the PENUT Trial 
(both consenting and non-consenting parents) were eligible to complete the ethics survey. 
  vii 
While completing the survey, parents (1) responded to statements about factors involved 
in their decision-making process, (2) rated their overall experiences in being asked to join 
the PENUT Trial, (3) described what ultimately led them to enroll or not to enroll their 
infants in the PENUT Trial, and (4) responded to demographic questions. 
 
Results: Thirty mothers of infants eligible for the PENUT Trial (22 consenting, 8 non-
consenting) were approached by a research study coordinator to complete the survey. Of 
the 22 consenting mothers, 10 were approached prenatally, and 12 were approached 
postnatally for the PENUT Trial. However, of the 8 non-consenting mothers, only 1 was 
approached prenatally, whereas 7 were approached postnatally for the PENUT Trial. The 
ethics survey was completed by 20 of 22 consenting mothers and 6 of 8 non-consenting 
mothers. The average rating among mothers of their overall experiences with the 
consenting process for the PENUT Trial was 3.77 (2.75 among non-consenters, 4.00 
among consenters) on a scale of 1 (= poor) to 5 (= excellent). Thirteen mothers preferred 
to be approached for the PENUT Trial by their baby’s neonatologist (6 preferred their 
OB/GYN, 5 preferred another doctor, 1 preferred a study coordinator, and 10 had no 
preference). In addition, 14 mothers preferred that the person approaching them was 
involved in the research trial (5 preferred person not involved, 2 preferred to be 
approached by those involved and not involved, and 9 had no preference). Lastly, 18 
mothers preferred to be approached prenatally (5 postnatally, and 7 had no preference). 
 
  viii 
Conclusions: Preliminary findings from the PENUT Trial ethics survey support the 
hypothesis that mothers prefer to be approached prenatally when considering enrollment 
of their newborn infants into the PENUT Trial. Survey responses also suggest that during 
the consent process mothers prefer to be approached by either (1) two neonatologists, 
with one responsible for the baby’s care and the other responsible for the research trial, or 
(2) one neonatologist who is involved in both the baby’s care and the research trial.  
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INTRODUCTION 
 
Overview 
This research thesis focuses on factors involved in acquiring informed parental 
consent in neonatal research and on ways that researchers can improve upon the parental 
consent process in the field of neonatal research.  
An infant is considered preterm when s/he is born before 37 weeks gestational age 
(a full-term birth is around 40 weeks). Moderately preterm births occur between 29 and 
33 weeks, and extremely preterm births occur between 23 and 28 weeks. Infants born 
prior to 23 weeks gestational age typically have very low survival rates. One of the 
primary concerns with premature deliveries is brain development and growth (PENUT 
Trial, 2016). The Preterm Erythropoietin Neuroprotection (PENUT) Trial is a nationwide 
study based out of the University of Washington (UW) in Seattle, Washington (PENUT 
Trial, 2016). Erythropoietin (Epo) is administered to adults and infants to increase red 
blood cell count in hopes of preventing anemia. According to the PENUT Trial website 
(https://penut-trial.org), the focus of the PENUT Trial is to administer Epo to extremely 
premature infants born 24 0/7 to 27 6/7 weeks, with the hypothesis that Epo will 
“decrease the combined outcome of death or severe neurodevelopmental impairment 
(NDI) from 40% to 30%” and “decrease moderate NDI from 60% to 40% measured at 
24-26 months corrected age.” The term neurodevelopment is “a word to describe how a 
baby develops and learns to do new things. This word includes motor or physical 
development, their ability to think and reason as they get older and also their ability to 
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see and hear. Infants born very early have more risk for neurodevelopmental problems 
than children born at term.” While some infants born very preterm will face development 
and growth problems, some preterm infants will have minimal or no neurodevelopment 
problems (PENUT Trial, 2016).  
As a supplement to the PENUT Trial, an ethics survey was designed by UW to 
study parental outlook towards enrollment of neonates into clinical trials (PENUT Trial, 
2016). According to the ethics survey consent form, this survey was designed to “help set 
a standard for consenting parents of premature infants for research trials” in a way that is 
“respectful, promotes trust, and presents a clear understanding of the research at hand.” 
The survey was conducted at only 9 of the 19 sites where the investigators of the PENUT 
Trial actively enroll patients. Beth Israel Deaconess Medical Center (BIDMC) in Boston, 
Massachusetts, is one of the PENUT Trial sites that enrolls patients in the PENUT Trial 
and conducts the ethics survey. At BIDMC, parents approached to participate in the 
PENUT Trial were also eligible to complete the ethics survey. The research study 
investigators conducted these surveys to learn more about parental experiences with the 
consenting process and how parents decided whether or not to enroll their extremely 
preterm infants in the PENUT Trial (PENUT Trial, 2016). The primary goal of the ethics 
survey and of this research thesis is to discover how researchers can improve the parental 
consenting process in the PENUT Trial as well as in future research trials involving 
newborn infants. Before discussing factors involved in acquiring parental consent, this 
research thesis will examine developmental outcomes associated with extreme 
prematurity and neuroprotective effects of Epo when administered to preterm infants. 
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Developmental outcomes associated with extreme prematurity 
Over the past few decades, survival rates for very low birth weight (VLBW) and 
extremely low gestational age (ELGA) infants have steadily increased. In 2010, a report 
was published in Pediatrics by Stoll et al. on morbidity and mortality rates for VLBW 
infants according to gestational age (GA). A total of 9575 infants born in participating 
hospitals were ELGA (between 22 and 28 weeks GA) and VLBW (401-1500 grams). The 
study measured newborn survival rates to discharge from hospital. Of the 9575 VLBW 
infants, 1060 died by or before 12 hours after birth, most of whom were 22 or 23 weeks 
GA. However, all GA infants experienced increased survival rates to discharge (Figure 
1). The investigators of the study concluded that although survival rates increased for 
many infants born by or after 24 weeks GA, morbidity rates among survivors continued 
to be high. The prevalence of morbidities of infants included 93% with respiratory 
distress syndrome, 46% with patent ductus arteriosus, 36% with late-onset sepsis, 16% 
with severe intraventricular hemorrhage, and 11% with necrotizing enterocolitis. Overall, 
infants born at lower GA were at greater risk for developing the aforementioned 
morbidities (Stoll et al., 2010). 
In 2007, Horsch et al. compared the magnetic resonance imaging (MRI) of all 
infants born before 27 weeks in the greater Stockholm area between January 2004 and 
August 2005. The study examined grey and white matter of the brain and used a scoring 
system to measure abnormalities. Horsche et al. (2007) concluded that 18% of ELGA 
infants from this study sample had incidence of moderate to severe white matter 
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abnormalities. At the time the study was published, follow-ups at 30 months’ corrected 
ages for participating infants were ongoing.  
 
Figure 1. Infant survival rates based on GA. Survival rates of 9575 VLBW infants 
born in participating hospitals between January 1, 2003, and December 31, 2007 (Stoll et 
al., 2010). 
 
 
The neurodevelopmental outcomes of extremely low birth weight (ELBW) infants 
have also been examined over longer periods of time. In 1995, La Pine, Jackson, and 
Bennett compared three separate studies that took place in the same neonatal intensive-
care unit (NICU) at UW between 1977 and 1980, 1983 and 1985, and 1986 and 1990. 
Two hundred and ten infants (birth weight [BW] < 800 grams) were admitted to the UW 
NICU during these time periods. The study investigators concluded that although the 
number of ELBW infants admitted to the UW NICU each year doubled from 1977 to 
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1990, “the prevalence of major neurosensory impairments did not differ significantly 
among the three study groups.” These results suggested that although more ELBW or 
ELGA infants were surviving to hospital discharge, the surviving infants were not 
experiencing decreased growth or developmental impairments (La Pine et al., 1995).  
Similar to the La Pine et al. (1995) study, a review of medical literature from the 
1990s published by Hack and Fanaroff in 2000 concluded that “the continuing toll of 
major neonatal morbidity and neurodevelopmental handicap are of serious concern.” The 
authors of the review found that lower GA and BW infants had higher rates of major 
neonatal morbidity. For example, 57%-86% of 23-week GA survivors, 33%-89% of 24-
week GA survivors, and 16%-71% of 25-week GA survivors developed chronic lung 
disease. The investigators also looked at the prevalence of serve disability, which 
included subnormal cognitive function, cerebral palsy, blindness, and/or deafness, among 
ELBW (BW < 800 grams) and ELGA (<26 weeks) infants. Of the 77 surviving 23-week 
infants, 34% were diagnosed with severe disabilities. In addition, 22%-45% of 24-week 
infants and 12%-35% of 25-week infants had severe NDIs. The authors concluded that 
upon comparison of infants born before the 1990s, the rates of NDIs remained relatively 
unchanged (Hack & Fanaroff, 2000). 
Although La Pine et al. (1995) and Hack and Fanaroff (2000) suggested that 
among extremely preterm (EPT) infants mortality rates were decreasing and morbidity 
rates were remaining the same, Wilson-Costello, Friedman, Minich, Fanaroff, and Hack 
published a study in 2005 in Pediatrics concluding that despite decreasing mortality 
rates, morbidity rates were increasing. Wilson-Costello et al. (2005) followed over 1000 
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ELBW infants (BW 500-999 grams) born during two separate periods in the same NICU 
(1982-89 and 1990-98). They concluded that rates of survival among the first group of 
ELBW infants were substantially lower than the latter group (49% and 67%, 
respectively). However, as mortality rates decreased, morbidity rates increased from the 
first time period to the second. The rates of sepsis, periventricular leukomalacia, chronic 
lung diseases, cerebral palsy, and deafness and the overall rate of NDIs increased in the 
latter group. The investigators concluded that although the survival rates of ELBW 
infants  increased, the risk of developing significant NDIs also increased, and that 
prospective parents of ELBW infants should be advised of this substantial risk “to 
facilitate decision-making in the delivery room” (Wilson-Costello et al., 2005). 
In more recent years, studies have been published analyzing the long-term effects 
of extremely preterm birth, especially in terms of education and classroom performance. 
In 2007, Marlow, Hennessy, Bracewell, and Wolke published a review in Pediatrics that 
focused on the neuromotor and executive-function deficits that may contribute to 
academic failures among EPT infants. Infants born by or before 25 weeks GA in the 
United Kingdom and Ireland in 1995 were studied six years later when they reached early 
school age. Of 308 children who met the aforementioned criteria and survived to early 
school age, 241 children (78%) were evaluated for this survey. Of the 241 evaluated 
children, 180 ELBW six-year-olds who did not have cerebral palsy were compared with 
160 of their same-age classmates (born full term) based on standardized cognitive and 
neuromotor assessments as well as teacher-based assessments of academic achievement. 
The investigators concluded that “impairment of motor, visuospatial, and sensorimotor 
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function, including planning, self-regulation, inhibition, and motor persistence, 
contributes excess morbidity over cognitive impairment in extremely preterm children 
and contributes independently to poor classroom performance at 6 years of age” (Marlow 
et al., 2007).   
A similar and even more recent study published in the Journal of Developmental 
and Behavioral Pediatrics (JDBP) sought to examine behavior disorders in EPT and 
ELBW children in kindergarten. Scott et al. (2012) “compared 148 EPT/ELBW children 
with 111 term-born normal birth weight classmates (control group) on reports of 
psychiatric symptoms obtained from parent interviews…parent and teacher ratings of 
behavior…and teacher ratings of social functions.” The researchers found higher rates 
(almost twice as high) of attention-deficit/hyperactivity disorder (ADHD) among 
EPT/ELBW children compared with normal birth weight children. In addition, the 
“EPT/ELBW group had much higher rates of teacher-identified disorders in attention, 
behavior self-regulation, and social functioning.” The findings of the study suggested that 
“early identification and intervention for these disorders are needed to promote early 
adjustment to school and facilitate learning progress” (Scott et al., 2012). 
In 2012, Vohr et al. published a collaborative study in the Journal of Pediatrics 
asking the question “Are outcomes of extremely preterm infants improving?” by using 
various editions of Bayley Scales of Infant and Toddler Development to evaluate motor, 
cognitive, and language skills of infants. Although the study team concluded that Bayley 
scores be interpreted cautiously, they did recommend that all ELBW infants be offered 
intervention services when discharged from the NICU (Vohr et al., 2012). 
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Similar to the Scott et al. (2011) and Vohr et al. (2012) studies, Lind et al. (2011) 
measured “the cognitive level and neuropsychological performance at 5 years of age in 
children” with VLBW (≤1501 grams) born between the years of 2001 and 2003. VLBW 
children (n = 97) were compared with healthy full-term children (n = 161) with mean BW 
of 3644 grams. When these children were five years old, their cognitive levels were 
evaluated with the Wechsler Preschool and Primary Scale of Intelligence. Lind et al. 
(2011) concluded that for the VLBW group, both their “mean intelligence” and their 
“neuropsychological performance” were considerably poorer than the comparison group. 
The research team concluded that the “assessments of cognitive level only at preschool 
age do not provide the information on neuropsychological deficit that is necessary for 
planning adequate educational support” (Lind et al., 2011). 
Fortunately, within the past few years, there have been increases in the number of 
published studies that have followed EPT infants for several years after initial discharge 
from the NICU. In line with studies published by Scott et al. (2011), Vohr et al. (2012), 
and Lind et al. (2011), the PENUT Trial aims to follow every enrolled baby for two years 
after discharge (PENUT Trial, 2016). At the end of two years, the trained research 
physicians will conduct a thorough in-person follow-up visit to evaluate the 
neurodevelopment and growth of the infants enrolled in the PENUT Trial. 
In addition to concerns of NDIs among ELBW or ELGA infants, necrotizing 
enterocolitis (NEC) is a serious illness that damages or destroys the intestinal cells of 
infants and has a high prevalence in EPT infants. NEC and sepsis are among the leading 
causes of death in ELBW or ELGA infants (PENUT Trial, 2016). A 2010 study was 
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published by Dr. Camilia Martin, a neonatologist and co-investigator of the PENUT Trial 
at BIDMC (Martin et al., 2010). Martin and her team of researchers aimed to “evaluate 
neurodevelopment after NEC and late bacteremia, alone and together” among 1155 
infants born between 23 and 27 weeks GA. They concluded that “children who had 
surgical NEC unaccompanied by late bacteremia were at increased risk of psychomotor 
developmental” problems and that “children who had both surgical NEC and late 
bacteremia were at increased risk of diparetic cerebral palsy and microcephaly.” 
However, the “children who had medical NEC with or without late bacteremia were not 
at increased risk of any developmental dysfunction.” The investigators supported the 
hypothesis that bowel injuries such as NEC and late bacteremia may trigger a cascade of 
systemic inflammatory events that have a potential effect on the developing brain. The 
results from this study suggested that there may be a strong correlation between 
neurodevelopment impairments and bowel injuries, which are two great concerns for 
extremely premature infants (Martin et al., 2010).  
Based on these studies, there has been a growing consensus that although the 
survival rates of ELBW or ELGA infants are increasing (decreasing mortality rates), the 
morbidity rates and the various developmental concerns associated with extreme 
prematurity are still troubling.  
 
Neuroprotective effects of erythropoietin (Epo) among extremely preterm infants 
 Over the past two decades, Epo has been used in NICUs around the U.S. and 
other parts of the world for preventing anemia and increasing red blood cell production. 
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Throughout its widespread use, many researchers discovered that Epo may have 
neuroprotective effects when administered to preterm infants (PENUT Trial, 2016). The 
PENUT Trial seeks to evaluate the neuroprotective effects that Epo may have when 
administered to infants born between 24 and 28 weeks GA (PENUT Trial, 2016). The 
PENUT Trial is a double-blind, nationwide, multicenter study with a large cohort of 
almost 1000 infants. Half of the infants enrolled in the PENUT study receive Epo 
(experimental group), and half receive a saline solution (placebo group). The first six 
high doses are given intravenously every other day, starting with the initial dose 
administered within the first 24 hours of birth. Afterward, the infants in the experimental 
group receive lower doses of Epo through subcutaneous injections three times a week 
until reaching 32 weeks GA. The infants enrolled in the control group do not receive any 
shots. The primary endpoint of the trial is neurodevelopmental status at two years of age 
(PENUT Trial, 2016). 
In 2007, investigators at the University of California, San Francisco (UCSF), were 
growing concerned that at the time there was no “effective treatment” for neonatal stroke, 
which often results in death of infants (Gonzalez et al., 2007). Gonzalez and his research 
team were primarily interested in studying the possible effects of Epo in terms of 
“cytoprotection and neurogenesis” and the ability of Epo to potentially “decrease 
subventricular zone morphologic changes following brain injury.” They concluded that 
the Epo treatment “significantly preserved hemispheric brain volume 6 weeks after 
injury” and that in addition, the Epo treatments “increased the percentage of newly 
generated neurons while decreasing newly generated astrocytes following brain injury, 
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without demonstrating long-term differences in the subventricular zone.” The results of 
this study supported the potential neuroprotective effects of erythropoietin (Gonzalez et 
al., 2007).   
Fauchère’s 2008 Swiss study involved the administration of high-dose 
recombinant human Epo (rEpo) to ELGA infants born 24 to 31 weeks, with the 
hypothesis that Epo “may reduce perinatal brain injury (intraventricular hemorrhage and 
periventricular leukomalacia) in very preterm infants and improve neurodevelopmental 
outcome” (Fauchère et al., 2008). The infants in the study were evaluated after being 
given a high-dose of Epo immediately after birth and again two days later. The 
researchers found no “significant adverse effects of early high-dose recombinant human 
erythropoietin treatment in very preterm infants” and discussed how these results would 
allow the team to “embark on a large multicenter trial with the aim of determining 
whether early high-dose administration of recombinant human erythropoietin to very 
preterm infants improves neurodevelopmental outcome at 24 months' and 5 years' 
corrected age” (Fauchère et al., 2008).  
In 2010, a German study investigated the neurodevelopmental outcomes of 
ELBW infants treated with rEpo by evaluating the infants at school age (Neubauer, Voss, 
Wachtendorf, & Jungmann, 2010). Of the 200 ELBW infants treated with rEpo between 
the years of 1993 and 1998, 171 survived to school age (10 to 13 years old). Of the 171 
surviving infants, 148 were evaluated in this study for neurodevelopmental outcomes. 
Table 1 compares the 89 school-age children who were born ELBW and treated with 
rEpo with the 57 ELBW children who were not treated with rEpo. Both the cognitive 
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outcomes and the overall outcomes were statistically significant (p < 0.05), and it was 
found that 55% of the rEpo group developed normally, whereas only 39% of the 
untreated group developed normally (Neubauer et al., 2010).  
The results were even more remarkable for the ELBW infants with 
intraventricular hemorrhage (IVH) who were treated with rEpo versus those with IVH 
who were not treated with rEpo (Neubauer et al., 2010). Table 2 compares the 46 school-
age children who were born ELBW and had IVH with the 100 ELBW children who did 
not have IVH. In the IVH group, 29 were treated with rEpo, and 17 were not. In the no 
IVH group, 60 were treated with rEpo, and 40 were not. The cognitive, overall, and 
school outcomes in the IVH group comparing rEpo treatment versus non-treatment were 
statistically significant (p < 0.02, < 0.005, and < 0.01, respectively), and it was found that 
52% of the IVH with rEpo group had normal overall outcomes at school age, whereas 
only 6% of the IVH without rEpo group had normal overall outcomes. None of the 
cognitive, overall, or school outcomes in the no IVH group comparing rEpo treatment 
versus non-treatment were statistically significant. Neubauer et al. (2010) concluded that 
their results “confirm the hypothesis of a neuroprotective effect of rEpo in ELBW infants 
with IVH” and that rEpo may offer “a promising preventative therapeutic option for the 
treatment of these high-risk infants.” 
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Table 1. Outcomes of school-age children born ELBW treated with rEpo and not 
treated with rEpo (Neubauer et al., 2010). 
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Table 2. Outcomes of school-age children born ELBW with IVH and without IVH 
treated with rEpo and not treated with rEpo (Neubauer et al., 2010). 
 
  
A UCSF Department of Neurology study published in Pediatrics in 2012 
measured the safety and pharmacokinetics of using Epo for neuroprotection in neonatal 
encephalopathy. Wu et al. (2012) sought to “determine the safety and pharmacokinetics 
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of erythropoietin (Epo) given in conjunction with hypothermia for hypoxic-ischemic 
encephalopathy (HIE)” and “hypothesized that high dose Epo would produce plasma 
concentrations that are neuroprotective in animal studies.” The team at UCSF concluded 
that administering Epo 1000 U/kg per dose intravenously—the same high dose given six 
times in the PENUT Trial (PENUT Trial, 2016)—“in conjunction with hypothermia is 
well tolerated and produces plasma concentrations that are neuroprotective in animals.” 
The investigators suggested that “a large efficacy trial is needed to determine whether 
Epo add-on therapy further improves outcome in infants undergoing hypothermia for 
HIE” (Wu et al., 2012). 
 In 2013, McAdams, McPherson, Mayock, and Juul from the UW published a 
study evaluating “long-term outcomes of 60 extremely low birth weight (ELBW) infants 
treated with or without three injections of high-dose erythropoietin (Epo).” Half of the 
ELBW infants received 3 doses of 500, 1000, and 2500 U/kg of Epo, whereas the other 
half of ELBW infants were in the control group and received no doses of Epo. The 
researchers did not identify any negative consequences of the Epo treatment and 
concluded that “Epo treatment is safe and correlates with modest improvement of 
neurodevelopmental outcomes” (McAdams et al., 2013). 
In February 2016, Ohls et al. published a second paper assessing the 
neurodevelopmental outcomes of preterm infants who were administered erythropoiesis-
stimulating agents (ESAs) such as darbepoetin and erythropoietin. Their first paper had 
been published two years prior to the 2016 paper and “reported improved 
neurodevelopmental outcomes at 2 years among infants treated with ESAs” (Ohls et al., 
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2016). In the second paper, the investigators assessed the same group of infants at 4 years 
of age and discovered that “children receiving ESAs performed better than those who 
received placebo on executive function tasks… evaluating inhibitory control and spatial 
working memory.” The investigators concluded that “ESA-treated infants had better 
cognitive outcomes and less developmental impairment at 3.5 to 4 years of age compared 
with placebo-treated infants” (Ohls et al., 2016). 
 Over the past few years, Epo has been increasingly used in research studies to 
assess its effectiveness in preventing NDIs and aiding in growth and development of EPT 
infants. Epo is widely considered safe for use in preterm infants, especially when Epo is 
administered in low doses, but the use of higher doses of Epo continues to be evaluated 
for safety and efficacy. Despite the research that supports the safety and effectiveness of 
Epo, communication between researchers and parents of EPT infants about the 
importance of Epo is imperative during the consenting process for a research trial.  
 
Factors involved in acquiring informed parental consent in neonatal research 
The field of neonatal research is still relatively new, and the number of research 
trials conducted with EPT infants remains low. This section of the introduction outlines 
studies conducted with pediatric patients and focuses on the roles of research trial 
investigators and parents throughout the consenting and enrollment process. 
John Zupancic (who is currently a neonatologist at BIDMC) conducted a 1997 
Canadian study that surveyed parents who had consented or denied consent for their 
infants to take part in one of three research trials in the NICU (Zupancic, Gillie, Streiner, 
 17 
Watts, & Schmidt, 1997). Zupancic et al. (1997) stated that “parents have the right to 
decide on behalf of their infants whether to enroll them in controlled clinical trials,” but 
the researchers wanted to assess “the degree to which such parental decisions are 
influenced by risk and benefit considerations compared with other factors.” Similar to the 
PENUT ethics survey (PENUT Trial, 2016), Zupancic et al. (1997) used a questionnaire 
that consisted of “sociodemographic items” as well as “scaled responses” that gauged 
parental attitude toward the risks and benefits of their infants’ illnesses, the research trials 
in which they were asked to enroll their infants, and their experiences with the consenting 
process. The research team discovered that parents making the consent decision to enroll 
their newborn infants into a research trial “are influenced by risk and benefit assessments, 
attitudes toward research, and the integrity of the consent process.” In addition, the 
investigators noted that “illness severity or sociodemographic characteristics do not seem 
to be of similar importance” and suggested that many parents “would prefer to have the 
physicians advise them whether to volunteer their infants for a clinical trial” (Zupancic et 
al., 1997).  
The Zupancic et al. (1997) study resembled this research thesis in three ways: (1) 
the work was conducted in an NICU, (2) the team approached consenting and non-
consenting parents, and (3) a questionnaire was used to obtain parental demographic 
information as well as parental feedback about the consenting process and their 
understanding of the studies.  
Another Canadian study that focused on examining the perceptions, attitudes, and 
beliefs of parents regarding research conducted on their newborn infants was published in 
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the Journal of Perinatology in 2002 by Singhal, Oberle, Burgess, and Huber-Okrainec. 
After surveying 72 parents of infants in the NICU and 159 parents of infants not admitted 
into the NICU, Singhal et al. (2002) concluded that “couples with newborns in NICU 
were significantly more likely to enroll their newborn in a study involving moderate risk 
and possible major direct benefit.” The investigators suggested that “parents believe 
research is necessary and want to be asked for consent, but many feel they have limited 
knowledge and would depend on their physician's advice” (Singhal et al., 2002).  
One year following this study, an investigation by Burgess, Singhal, Amin, 
McMillan, and Devrome (2003) aimed to better understand what the perceptions of 
parents of infants in the NICU are of the process of enrolling their infants into research 
studies. The results of the questionnaires and surveys used by Burgess et al. (2003) were 
similar to Zupancic et al. (1997) in regard to the role of parental decision-making. They 
found that “Overall the parents did not support the suggestion that decision making about 
enrollment be taken away from parents and put into the hands of doctors.” In addition, 
the research team suggested that “the healthcare team should support parents in their role 
of decision maker, enhance availability of the research staff, and provide more 
information about the research” (Burgess et al., 2003).  
A study published by Ballard, Shook, Desai, and Anand in 2004 in the Journal of 
Perinatology focused on the difficulty of acquiring valid informed consent from parents 
to enroll newborn infants into research trials in the NICU. The researchers surveyed 64 
sets of parents who had enrolled their NICU infants into a research study which focused 
on “neurological outcomes and pre-emptive analgesia in the neonate (NEOPAIN).” The 
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team discovered that 7.8% of 64 parents “had no recollection of the NEOPAIN study or 
of signing consent.” Of the remaining 59 parents, “only 67.8% understood the purpose of 
the study, with a higher proportion of mothers than fathers knowing the purpose of the 
study (73.3% versus 57.1%),” and “of those who understood the purpose of the study 
95% were able to verbalize the benefits, but only 5% understood any potential risks.” The 
investigators also suggested that “to maximize validity of consent in the 
antenatal/perinatal population every effort should be made to include mothers in the 
consent process” and “additional attention during the consent process should be given to 
possible risks of the study” (Ballad et al., 2004). 
Most recently in 2015, a multicenter cohort study based out of another Harvard 
teaching hospital, Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts, was 
implemented to “evaluate the feasibility of conducting a pediatric palliative care random 
controlled trial (PPC-RCT) in pediatric cancer patients” (Dussel et al., 2015). Over the 
five years this research study was conducted, 104 patients were enrolled, of which 87 
completed the study. Dussel et al. (2015) concluded that a “PPC-RCT in children with 
advanced cancer was feasible,” “post-inclusion retention [was] adequate,” and “many 
families participated for altruistic reasons.” The research team suggested the following 
strategies to increase the feasibility of future PPC-RCTs: “increasing target population 
through large multicenter studies, approaching sicker patients, preventing exclusion of 
certain patient groups, and improving data collection at end of life.” Although this study 
(Dussel et al., 2015) did not involve NICU infants, it was relevant to this research thesis 
because it focused on factors influencing the parental consent process. 
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The importance of the consent process was brought to the forefront by the 
controversy around the Surfactant, Positive Pressure, and Oxygenation Randomized Trial 
(SUPPORT) (SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal 
Research Network, 2010). The investigators of this nationwide, multicenter clinical trial 
led by Finer and Carlo sought to evaluate the role of continuous positive airway pressure 
(CPAP) as a means of respiratory support in the delivery room and to determine the 
optimal level of oxygen for prevention of retinopathy of prematurity (ROP). The 
investigators were criticized that “the informed consent document that the parents of the 
newborns enrolled in SUPPORT had signed had not adequately explained the risks of 
participation in the research” (Drazen, Solomon, Morrissey, & Greene, 2015). Drazen et 
al. (2015) published an editorial in the New England Journal of Medicine that “the 
research community, ourselves included, were dumbfounded” by the accusations that 
some of the neonates participating in the study were injured as a result of the study and 
that it was the fault of the study investigators for not informing them that these injuries 
would occur. The investigators explained that “before the study was completed, the risk 
of death at an oxygen saturation above 85% was unknown” and further noted “how could 
the investigators be faulted for failing to disclose an unknown risk?” Ultimately, “the 
judge decided that the plaintiffs had not shown reasonable evidence that the injuries the 
newborns had sustained resulted from participation in the research study” rather than 
complications associated with premature birth (Drazen et al., 2015).  
The foremost challenge for study staff during enrollment of neonates into the 
PENUT Trial is the 24-hour window after the baby is born in which s/he must be enrolled 
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in the study to receive the first high dose of Epo and undergo blood draw, urine 
collection, and head ultrasound (PENUT Trial, 2016). Ideally, the research team 
approaches the pregnant mothers who are within the window of 24 to 28 weeks GA while 
they are on the antepartum floor of the hospital. In this way, the mothers are provided 
with information regarding the study and have time to discuss the potential risks and 
benefits of Epo and what it would entail for the baby to be enrolled in PENUT. After 
mothers have a few days to think about the study and discuss the PENUT Trial with their 
partners and family members, the study staff meets with the parents to discuss any 
questions that they may have about the study. The ultimate goal of the researchers is to 
explain the study to parents clearly and thoroughly and to obtain consent before the baby 
is born. If and when the baby is born within 24 to 28 weeks GA, the research team does 
not have to add the extra burden of approaching the mother of an extremely preterm 
infant immediately after delivery. However, many times mothers are transferred from 
other regional hospitals and deliver eligible infants immediately. In this case, the study 
team’s only option is to approach, inform, and obtain consent within the stressful 24 
hours after birth. The PENUT Trial ethics survey was created to help researchers improve 
the consenting process by understanding what parents of newborn EPT infants experience 
when they are approached by research study investigators to enroll their infants into the 
PENUT Trial (PENUT Trial, 2016).  
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Objectives 
The hypothesis of this research thesis is that parents approached before their 
extremely preterm infants are born will have more time to: (1) research and ask questions 
about the study, (2) discuss benefits and risks of the study, and (3) seriously consider 
enrolling their infants into the PENUT Trial. This research thesis focuses on: 
 Parental demographic and socioeconomic characteristics.  
 Parental responses regarding the consent process.  
 Parental preferences regarding the consent process.  
 Factors involved in parental decisions to enroll infants in the research trial. 
 Parental ratings of overall experience with consent process.  
 Suggestions for improving the parental consent process in research trials 
involving neonates. 
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METHODS  
 
Institutional Review Board (IRB) approval for PENUT ethics survey at BIDMC 
The PENUT Trial ethics survey supplement (Appendix 1) received IRB approval 
at BIDMC in September 2015. At the time of the survey’s approval, the guidelines for the 
survey were two-fold: (1) all parents of infants who were eligible for the PENUT Trial 
and were approached for PENUT Trial enrollment by the study team were also eligible 
for the survey and (2) surveys needed to be completed with parents when their infants 
were between days of life (DOL) 15 and 28. As of December 21, 2015, the window to 
approach parents to complete the ethics survey was extended from DOL 15 and 28 to 
DOL 15 and 43. Eligible parents who completed the survey were rewarded with a $20 
Amazon gift card. For purposes of this research thesis, an IRB amendment was submitted 
to allow the research study coordinator to (1) contact all parents who were approached 
regarding enrollment of their eligible preterm infants in the PENUT Trial (despite the age 
of the baby at the time of contact) and (2) ask all parents an additional set of survey 
questions, mostly demographic-based (Appendix 2). However, these parents were not 
eligible for the Amazon gift card, and survey responses were entered into a separate 
database which was used solely for purposes of this research thesis.  
 
PENUT Trial enrollment and completion of PENUT ethics survey  
The first infants enrolled in the PENUT Trial at BIDMC were twin girls born in 
early April 2014. Between April 2014 and February 2016, the total infants enrolled in 
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PENUT at BIDMC were 37. Of the 37 infants enrolled in PENUT, there were 5 sets of 
twins, so in total, 32 sets of parents provided consent for one or more infants into the 
PENUT Trial. These 32 sets of parents were all eligible to complete the survey and to be 
categorized as the “consenting group” for purposes of this research thesis. As a part of the 
PENUT Trial, mothers of all infants enrolled in the PENUT Trial were contacted for 
follow-up at time of discharge and at 4, 8, 12, and 18 months post-discharge. For 
purposes of this research thesis, ethics surveys were conducted over-the-phone with 
mothers of discharged PENUT infants at one of the scheduled follow-up periods. 
Investigators at BIDMC have roughly a 50% enrollment rate for the PENUT 
Trial. For example, in the year 2015, 13 infants were enrolled into the PENUT Trial, but 
parents of 12 eligible infants did not enroll their infants in the PENUT Trial. For purposes 
of this research thesis, parents who did not consent to the PENUT Trial prior to the start 
of the ethics survey in September 2015 were not contacted to complete the ethics survey. 
Not only would these parents not have any financial incentive to complete the survey, but 
also many of them would not have interacted with current PENUT study staff. Therefore, 
the “non-consenting” group for purposes of this research thesis was only comprised of 
the 8 sets of parents who were approached but did not consent to enrollment of their 
eligible infants into the PENUT Trial between September 2015 and February 2016.  
 
The PENUT Trial ethics survey  
 The PENUT Trial ethics survey (Appendix 1) asked if parents provided consent to 
enroll their infants into the study and whether they listened to the PENUT study 
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description before making their decisions. Parents also shared their experiences learning 
about the PENUT Trial—who approached them, when they were approached, and how 
many times they spoke with this person. All survey responses were anonymous. 
Depending on when the PENUT Trial team asked parents for permission to enroll 
their eligible infants into the study, parents were asked to imagine if it would be more or 
less stressful to have been asked for permission: (1) after the baby was born (if they were 
actually asked before) or (2) before the baby was born (if they were actually asked after). 
The survey also asked questions about when and by whom parents would prefer to be 
asked for permission to consent their infants into a research trial.  
The survey also asked parents to “agree” or “disagree” to several statements about 
factors involved in their decision-making process, as well as to respond to 10 “true” or 
“false” statements about the PENUT Trial. In addition, parents were asked to: (1) rate 
their overall experiences in being asked to join the PENUT Trial, (2) comment on what 
they liked or disliked about the consenting process, and (3) describe why they chose to 
enroll or not to enroll their infants in the PENUT Trial. At the end of the survey, parents 
responded to demographic-based questions and an additional questionnaire (Appendix 2).  
 
Statistical Analyses 
No statistical analysis was completed for purposes of this research thesis due to 
the small sample size. This is a convenience sample and all of the results are qualitative.   
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RESULTS 
 
Screening, enrollment, and completion of PENUT ethics survey  
BIDMC began screening eligible patients for enrollment into the PENUT Trial in 
February 2014. Since then, 65 mothers delivered infants (either singletons or twins) who 
were within the GA window of 24 weeks 0 days and 27 weeks 6 days and met all 
inclusion criteria for the PENUT Trial. As shown in Figure 2, of those 65 mothers, 32 
consented to enrolling their infants into the PENUT Trial, and 33 declined consent 
(49.2% consenting rate).  
For PENUT infants in the NICU, ethics surveys were conducted in person with 
mothers when the baby was between 2 and 6 weeks of life. Of the 22 consenting mothers 
who were approached, 20 ethics surveys were completed either in person or over the 
phone. Of the 12 consenting mothers who did not complete the survey (10 unapproached, 
2 approached), 6 mothers were not contacted because they were not within the window 
for a scheduled follow-up, 3 mothers were not contacted because their infants had died, 1 
mother was no longer in the country, 1 mother withdrew her baby from all aspects of the 
PENUT Trial, including follow-ups and surveys, and 1 mother never responded to the 
phone calls and e-mails made by the research assistant conducting the surveys.   
Completing ethics surveys with mothers who did not consent to the PENUT Trial 
was more challenging. Only non-consenting mothers who were approached for the 
PENUT Trial starting in September 2015, when the ethics survey received IRB approval 
at BIDMC, were approached for the survey. Of the 8 mothers who did not consent to the 
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PENUT Trial between September 2015 and February 2016, 6 surveys were completed. 
The 2 non-consenting mothers who did not complete the survey were a mother of a baby 
who was transferred to a different hospital soon after birth and a mother who took the 
survey home with her but never returned it. The research study staff had difficulties 
contacting this latter mother because of legal and social work issues. 
Minimal demographic information, as well as information regarding when and by 
whom mothers were approached for the PENUT Trial, is included in the results section 
wherever appropriate. The sample size (as seen in Figure 2) is n = 22 for consenting 
mothers and n = 8 for non-consenting mothers. In all cases but one (when the father 
completed the survey), the parent responding to the survey was the mother of the infant. 
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Figure 2. Screening, enrollment, and completion of PENUT ethics survey. This figure 
breaks down the number of mothers eligible to consent infants into the PENUT Trial, the 
number of mothers who provided consent for PENUT Trial versus those who did not 
provide consent, the number of mothers approached for the PENUT ethics survey versus 
those who were not approached for the ethics survey, and lastly, the number of mothers 
who completed the ethics survey. The highlighted boxes indicate the number of mothers 
who were approached for the PENUT ethics survey. 
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Demographic and social factors of parents approached for PENUT ethics survey 
 As seen in Table 3, more than half of the mothers approached for the PENUT 
ethics survey were over the age of 33, with a large number of them over the age of 36. 
The same was true for the fathers of the infants. Half of the mothers approached for the 
survey were white or Caucasian (n = 15), with several mothers who identified as 
Hispanic or Latino (n = 7), Black (n = 5), or Asian (n = 3). 
 
Table 3. Infant characteristics and parental demographics.  
 Consenters (n=22) Non-consenters (n=8) Total (n=30) 
Gestational age     
24 weeks 6 2 8 
25 weeks 3 2 5 
26 weeks 5 3 8 
27 weeks 8 1 9 
Maternal age at delivery    
<26 3 1 4 
27-29 3 1 4 
30-32 4 1 5 
33-35 3 4 7 
36+ 9 1 10 
Paternal age at delivery    
<26 3 1 4 
27-29 2 0 2 
30-32 4 0 4 
33-35 3 1 4 
36+ 8 0 8 
Not reported 2 6 8 
Race/ethnicity (maternal)    
      White/Caucasian 11 4 15 
Hispanic/Latino 5 2 7 
Asian 2 1 3 
Black 4 1 5 
Race/ethnicity (paternal)    
      White/Caucasian 10 1 11 
Hispanic/Latino 4 1 5 
Asian 2 0 2 
Black 4 0 4 
Not reported 2 6 8 
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When breaking down parental education levels (Table 4), the numbers of mothers 
and fathers who reported having attained a college degree were roughly the same, 10 and 
11, respectively. However, none of the fathers reported having completed a graduate 
school degree, whereas 3 of the mothers approached for the ethics survey had completed 
a graduate degree. When asked about current occupations, mothers and fathers reported 
careers in several fields (Table 4). Eleven surveyed mothers reported being employed in 
healthcare, management, or finance, 6 reported other forms of employment, 7 reported 
being unemployed, and 6 did not report their occupations. Every completed ethics survey 
listed that the father had some form of employment. Common forms of paternal 
employment included marketing, sales, engineering, finance, healthcare, construction, 
maintenance, and other occupations. With regard to marital status, 18 of the 30 parents 
reported being married, but 8 of the 30 parents reported never being married. Although 
parents approached for the PENUT ethics survey came from various household incomes, 
43.3% reported having household incomes greater than $55,000, 36.7% reported having 
household incomes less than $55,000, and 20% did not report household incomes.  
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Table 4. Parental socioeconomic characteristics.  
 Consenters (n=22) Non-consenters (n=8) Total (n=30) 
Highest level of education (maternal)    
Some high school or less 2 0 2 
High school graduate 5 0 5 
Some college 4 2 6 
College graduate 7 3 10 
Some graduate school 1 0 1 
Graduate degree 3 0 3 
Not reported 0 3 3 
Highest level of education (paternal)    
Some high school or less 2 0 2 
High school graduate 3 1 4 
Some college 4 1 5 
College graduate 10 1 11 
Some graduate school 1 1 2 
Graduate degree 0 0 0 
Not reported 2 4 6 
Maternal occupation    
Finance 2 0 2 
Management 3 2 5 
Healthcare 3 1 4 
Other professions 5 1 6 
Not employed 7 0 7 
Not reported 2 4 6 
Paternal occupation    
Marketing/Sales  3 0 3 
Engineering/IT 3 1 4 
Finance/Consulting 2 0 2 
Healthcare 2 0 2 
Construction 2 1 3 
Maintenance/Labor 3 0 3 
Other professions 5 2 7 
Not reported 2 4 6 
Marital status    
Never married/Engaged 7 1 8 
Married 13 5 18 
Domestic partnership 0 0 0 
Separated 1 0 1 
Divorced 1 0 1 
Widowed 0 0 0 
Not reported 0 2 2 
Household income     
$30,000 or less 5 1 6 
$30,000-$55,000 3 2 5 
$55,000-$95,000 5 1 6 
>$95,000 6 1 7 
Not reported 3 3 6 
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When parents responding to the survey were asked how far they lived from 
BIDMC when they were commuting to and from the NICU, 14 of 30 reported living less 
than 10 miles from the hospital (Table 5). One mother even reported that during the 
majority of her baby’s stay in the NICU, she took part in a parent-sleep-stay where she 
remained with her child in the hospital. Seventy percent of parents commuted to and from 
BIDMC by private car, with only a small number of parents using public transportation 
or taxi cab services. Although 33.3% of mothers reported spending on average less than 4 
hours per day with their infants in the NICU, 16.7% spent 4-6 hours, 6.7% spent 6-8 
hours, 10% spent 8-10 hours, 16.7% spent 10 or more hours, and 16.7% did not report the 
daily number of hours they spent in the NICU. The majority of parents had private health 
insurance, most often Blue Cross/Blue Shield. However, all extremely premature infants 
were eligible for MassHealth, a form of public health insurance in Massachusetts, and the 
majority of the infants were enrolled in MassHealth as a supplemental insurance. 
Table 5 also lists different languages and religions of the parents completing the 
PENUT ethics survey. For 83.3% of responding parents, English was reported as the 
primary language spoken at home. The importance of religion and spirituality was 
relatively evenly split across the spectrum from “very important” to “not at all important” 
for responding parents. Eight of the 30 parents reported being Catholic, 8 reported having 
no religion (including atheist and agnostic), 5 reported being Protestant, and 4 reported 
having other religions.  
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Table 5. Additional parental demographics.  
 Consenters (n=22) Non-consenters (n=8) Total (n=30) 
How far parents lived from BIDMC 
while baby in NICU 
   
<10 miles 10 4 14 
10-20 miles 2 2 4 
20-30 miles 3 0 3 
30-40 miles 5 0 5 
40+ 2 1 3 
Not reported 0 1 1 
Mode of transportation to NICU    
Private car 18 3 21 
Taxi/Uber/Lyft 0 2 2 
Public transportation 2 0 2 
Not reported 2 3 5 
Hours parent spent in NICU daily    
<4 8 2 10 
4-6 3 2 5 
6-8 2 0 2 
8-10 2 1 3 
10+ 5 0 5 
Not reported 2 3 5 
Health insurance type    
Private Insurance    
   Blue Cross/Blue Shield 8 3 11 
   Cigna  2 1 3 
   Tufts 2 2 4 
   Other private insurance 5 0 5 
Public Insurance    
   MassHealth 3 0 3 
   Neighborhood Health 2 1 3 
Not reported 0 1 1 
Primary language spoken at home     
English 17 8 25 
Spanish 2 0 2 
Other 3 0 3 
Not reported 0 0 0 
Importance of religion/spirituality     
Very important 4 3 7 
Important 4 2 6 
Somewhat important 6 0 6 
Not at all important 6 1 7 
Not reported 2 2 4 
Religious affiliation     
Catholic 7 1 8 
Protestant  3 2 5 
Other religion 3 1 4 
None 7 1 8 
Not reported 2 3 5 
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Parental feedback about when and by whom they were approached for PENUT Trial 
Table 6 shows that among consenting mothers who were approached for the 
ethics survey, approximately half were approached prenatally and half postnatally. 
However, among non-consenting parents, 7 out of 8 of them were approached 
postnatally.  
All but two parents approached for the PENUT ethics survey were first 
approached by someone involved in the PENUT Trial, either a study coordinator or a 
doctor not caring for the mother or the baby, but often it was both a coordinator and 
doctor involved in PENUT approaching parents together (Table 6). Regarding 
enrollment, 43.3% of parents made their decisions after speaking to PENUT Trial study 
staff at least twice, and 30% after speaking to PENUT Trial study staff three or more 
times. Only 26.7% of parents reached their conclusions to enroll or not to enroll infants 
after speaking to PENUT Trial study staff just once. For 19 of the 30 mothers, their 
decisions on enrollment were reached after a few hours, but for 10 mothers, their 
decisions required a few days, and for 1 mother, her decision took over a week to reach. 
Most mothers spoke with their partners as well as other family members and other nurses 
or doctors before reaching their decisions. Overall, among parents responding to the 
question “How much did you trust the person who talked to you about the PENUT 
Trial?” on a scale of 1 (did not trust at all) to 5 (trusted completely), the average response 
among all mothers was 4.15 (Table 6). 
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Table 6. Parental responses regarding the consent process.  
 Consenters (n=22) Non-consenters (n=8) Total (n=30) 
When were you first approached about 
PENUT Trial?  
   
Before baby was born 10 1 11 
After baby was born  12 7 19 
Who first approached you to ask about 
participating in the PENUT Trial? 
   
Neonatologist caring for baby 1 0 1 
Neonatologist NOT caring for    
baby 
3 3 6 
Study coordinator  9 3 12 
Neonatologist NOT caring for  
baby AND study  
coordinator(s) 
9 2 11 
Was this person involved in the PENUT 
Trial? 
   
Yes 21 7 28 
No 1 1 2 
Did you talk to that person more than 
once before deciding? 
   
      No, just once 4 4 8 
Yes, twice 10 3 13 
Yes, three or more times 8 1 9 
Not reported 0 0 0 
Over what time period did you talk to 
this person before deciding? 
   
      Hours 13 6 19 
Days 8 2 10 
Weeks 1 0 1 
Did you talk to anyone else before 
making your decision?* 
   
Yes 17 4 21 
    My partner 17 4 21 
    Family member 6 1 7 
    Nurse or another doctor 6 1 7 
    Research coordinator 0 0 0 
No 5 4 9 
How much did you trust the person who 
talked to you about the PENUT Trial? 
   
      1 (Did not trust at all) 0 0 0 
2 1 1 2 
3 0 1 1 
4 8 1 9 
5 (Trusted completely)  8 0 8 
Not reported 5 5 10 
*Mothers chose more than one option in response to this survey question. 
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Parental preferences about when and who should approach them for PENUT Trial 
Regardless of when consenting parents were first approached about the PENUT 
Trial, 17 of 22 consenting parents signed the consent forms after their infants were born 
(Table 7). Over three-fourths of consenting parents reported that the person who first 
approached them about PENUT was also the one to acquire consent.  
Both consenting and non-consenting parents were asked when and by whom they 
preferred to be approached regarding the PENUT Trial. Eighteen of 30 parents reported 
they preferred being approached before the baby was born, only 5 said after the baby was 
born, and 7 had no preference or did not respond to the question. When parents were 
asked whom they would most and least prefer to approach them regarding the PENUT 
Trial, many did not have a preference or did not respond to this line of questioning. 
However, the majority of parents most preferred to be approached by the baby’s doctor 
and least preferred to be approached by a research study coordinator. Fourteen of the 30 
parents reported a preference that the person approaching them about PENUT should be 
involved in the study, 5 mothers preferred the person approaching them not to be 
involved in the study, 2 mothers preferred to be approached by those involved and not 
involved in the study, and 9 mothers had no preference or did not respond to this question 
(Table 7). 
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Table 7. Parental preferences regarding the consent process.  
 Consenters (n=22) Non-consenters (n=8) Total (n=30) 
When did you first sign the consent 
form? (Not applicable to non-
consenters) 
   
Before baby was born 5 N/A N/A 
After baby was born  17 N/A N/A 
At the time you signed the consent 
form, was the person who acquired 
this consent the same person who 
had approached you the first time?   
   
Yes 17 N/A N/A 
No 4 N/A N/A 
Unsure/not reported 1 N/A N/A 
Whom would you MOST prefer to 
ask for your permission for your 
baby to participate in a research 
trial?*  
   
      Your OB 5 1 6 
Your baby’s doctor 11 3 13 
Doctor NOT caring for    
baby 
3 2 5 
Study coordinator  1 0 1 
No preference/not reported 7 3 10 
Would you prefer if that person 
was involved or not involved in the 
research trial? 
   
      Involved 10 4 14 
Not involved 4 1 5 
Both 1 1 2 
No preference/not reported 7 2 9 
Whom would you LEAST prefer to 
ask for your permission for your 
baby to participate in a research 
trial?* 
   
Your OB 1 0 1 
Your baby’s doctor 0 1 1 
Doctor NOT caring for    
baby 
4 1 5 
Study coordinator  6 2 8 
No preference/not reported 12 5 17 
When would you prefer that this 
person ask for your permission? 
   
      Before baby was born 14 4 18 
After baby was born  4 1 5 
No preference/not reported  4 3 7 
*Mothers chose more than one option in response to this survey question. 
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Parental stress levels during consent process for PENUT Trial 
Among parents who were approached before their infants were born, the majority 
of them reported that it would have been more stressful if they were approached 
postnatally (Table 8). Among parents approached after their infants were born, the 
majority of them reported that it would have been less stressful if they were approached 
before their infants were born (Table 9).  
 
Table 8. Stress levels if parents are approached postnatally.  
 Consenters 
approached 
prenatally (n=10) 
Non-consenters 
approached 
prenatally (n=1) 
Total approached 
prenatally (n=11) 
Now imagine that you had been 
asked for permission AFTER your 
baby was born. Do you think that 
would have felt _______________ 
than being asked BEFORE your 
baby was born (as you were)? 
   
      1 (less stressful) 0 0 0 
2 0 0 0 
3 (no difference) 2 1 3 
4 1 0 1 
5 (more stressful)  4 0 4 
Not reported 3 0 3 
 
Table 9. Stress levels if parents are approached prenatally.  
 Consenters 
approached 
postnatally (n=12) 
Non-consenters 
approached 
postnatally (n=7) 
Total approached 
postnatally (n=19) 
Now imagine that you had been 
asked for permission BEFORE your 
baby was born. Do you think that 
would have felt _______________ 
than being asked AFTER your baby 
was born (as you were)? 
   
      1 (less stressful) 5 3 8 
2 1 1 2 
3 (no difference) 4 1 5 
4 0 0 0 
5 (more stressful)  1 0 1 
Not reported 1 2 3 
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Feedback from non-consenting parents responding to PENUT ethics survey 
When non-consenting mothers were asked why they did not give permission for 
their infants to participate in the PENUT Trial, most of them explained that they had been 
approached after the baby was born and felt they were short on time or were not in the 
mental, emotional, or physical condition to provide consent. When mothers were asked 
when they preferred to be approached, most of them responded that they wished they 
were approached before their infants were born because it was a less stressful time and 
there was more time to consider the study. Commentary and suggestions from a few non-
consenting mothers included: 
 “Less stressed [before baby born], more time to think about it and research it.”  
 “In a different mental space before he was born—we could've considered the 
study when it was theoretical/hypothetical; would've been hard though 
because short time prior to delivery.”  
 “The 24-hour after birth deadline for enrollment creates a time crunch.” 
 “We changed our mind after talking to nurses and doctors in the NICU but by 
then it was too late.”  
When mothers were asked whom they would most prefer to approach them 
regarding the PENUT Trial, many mothers responded that they would prefer the baby’s 
doctor or another doctor to approach them about the study, and two of the mothers 
reported that they would least prefer a research study coordinator to approach them. 
Some of the comments from these mothers were: 
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 “[Research study coordinator] does not come across as having the baby's best 
interest at heart. Just filling the slot because she qualifies for criteria of study.” 
 “Because baby's doctor knows more about baby's health.” 
 “Wish doctors/nurses more educated about study—more fact/opinion about 
study.” 
Mothers were also asked to comment on what they liked and disliked about 
PENUT. Some mothers responded positively:  
 “It was a warm delivery [but] it just would have come off better if asked with 
a nurse or doctor from the NICU present.” 
 “Person requesting was respectful, brought in doctor involved in study to 
answer questions.” 
One mother, however, was unhappy that she was approached while she was 
having contractions, saying, “Please do not ask mothers when they are in labor.” 
When asked why they chose not to enroll their infants in the PENUT Trial, 
mothers responded with a variety of reasons: 
 “Didn't know enough about it when asked. Then when we asked NICU nurses 
and doctors we wanted to enroll but it was too late.” 
 “Didn't read brochure, except safety/risks; saw ‘death’ and became 
irrational…wish more safety info in brochure and explained by study staff.” 
 “Unable to participate in follow-up because will be out of country.” 
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Feedback from consenting parents responding to PENUT ethics survey 
Roughly half of the consenting mothers were approached prenatally and half were 
approached postnatally. When mothers who provided consent prenatally were asked if 
they would have felt more stressed if they were approached after the baby was born, they 
responded with comments suggesting that they preferred not to be approached 
postnatally: 
 “Because that's when I really started getting depressed.” 
 “So many other decisions to make when baby born it rocks your world—I was 
in recovery for 24 hours, that's how bad I was doing, [and] I wouldn't have 
even been able to give consent; husband wouldn't have wanted to make 
decision without research and my ‘okay.’ ” 
 “After dealing with hormones, not in right state of mind.” 
Mothers who provided consent postnatally were asked if they would have felt 
more stressed if they were approached before the baby was born. They responded with 
mixed comments, suggesting that some preferred being asked after the baby was born 
because they did not want to imagine giving birth to an extremely preterm infant: 
 “Probably wouldn't have guaranteed anything, would've probably said no, 
would've wanted to wait to see how he was doing…probably would’ve said 
no if before.” 
 “Because you never want your baby born this early so talking about this 
option…you just don't want this.” 
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 “In denial—I never thought my kid would come early—I don't know how I 
would've reacted to you guys; but I would do anything that benefits…because 
my mind not there—if I was told that I was going to have a preemie, I 
wouldn’t believe it.” 
By contrast, other mothers who provided consent postnatally indicated they would 
have much rather preferred prenatal consent: 
 “Situation very traumatic being how early baby is, but even with all worries 
aside, if opportunity to consent before birth, it would be better.”  
 “Study team came 1-2 hours post C-section; really hard time—would not 
recommend—wasn't really with it and wasn't listening…didn’t feel as stressed 
out before [baby was born] as compared with after.”  
 “If before, we would have time to understand…especially for foreigners, need 
time to understand…right when they were born we were just so confused.” 
 “I was approached hours after emergency C-section while many nurses were 
in and out, concerns of our baby still fresh.” 
 “In circumstances you can do it before, because we have a 24 hour deadline, 
and it’s a big decision to make in 24 hours.” 
When mothers were asked who they would most prefer to have approached them 
for the PENUT Trial, most consenting mothers responded that they would prefer the 
baby’s doctor, but some replied that they would prefer the obstetrician or gynecologist 
taking care of them. Other consenting mothers indicated that they least preferred a 
research study coordinator to approach them. Some of their comments were: 
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 “Because sometimes overwhelming, when dealing with premature infants, 
would've been better to be approached with baby's doctor rather than someone 
random who is doing study.” 
 “If the doctors I knew would guide me through the process and recommend 
which studies to do and which not to do; you trust them [and] you become 
more on board—that’s why I asked so many people their opinions.” 
However, many consenting mothers did not have a strong preference regarding 
who should approach them. They primarily wanted to hear neutral testimony from those 
involved in the study as well as those not involved in the study: 
 “Preferred to hear from doctors caring for me and baby and those not caring 
for us, as well as those involved in study and those not; want to hear parent 
testimony because unbiased.” 
  “Everyone from NICU all great—no preference but don't want study to 
interfere with baby's treatment.” 
 “Neutral opinion/explanation for risks about med.” 
 “I can go either way it doesn't matter to me.” 
 “Everyone has an input, I'd like to hear everyone's input.”  
 “No preference—everyone was helpful but when thinking about withdrawing, 
wish someone told me it was okay to withdraw instead of making me feel 
overwhelmed; great program.” 
Mothers were asked to comment on what they liked and disliked about PENUT. 
Some responded positively:  
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 “Selling point was Boston Children’s Hospital involved, puts parents at ease.” 
 “Being such an early baby, another potential positive thing that could come 
out of this. Seeing a familiar face every day.” 
 “Do this study in Puerto Rico because in San Juan they don't know how to 
take care of preemies; brother with same age infants died.” 
 “I think the whole program is great, I withdrew because overwhelming, a lot 
going on medically, one thing I could control/take off mind, so I wanted to 
back out [of PENUT].” 
However, one mother gave a poor rating “not because of people [involved with 
PENUT] but because of the timing and situation; felt overwhelmed; listening but not 
absorbing information; if husband wasn't there, would not consented; no way I would 
have agreed within 24 hours without husband.” 
When asked why they chose to enroll their infants in the PENUT Trial, mothers 
responded with a variety of reasons: 
 “Not expecting to have premature baby…open to try anything…seemed more 
beneficial to do it than not do it.” 
 “When asked, I felt if they do study they will watch baby more…relieved that 
someone would be with him; only problem: they had to pinch them a lot.” 
 “Main reason enrolled in study to improve care for child; hoping she gets ‘real 
deal’ and hopefully good outcome from it.” 
 “Mainly knowing it would help her and other infants down the road 
potentially. Half of the stuff in the NICU is a result of some research.” 
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Factors involved in parental decision-making to enroll infants into PENUT Trial 
 Tables 10-14 summarize the responses from surveyed parents. Parents responded 
to a series of statements that gauged what factors were important to them when deciding 
to enroll or not to enroll their infants into the PENUT Trial. 
As seen in Table 10, most parents, regardless of their decision to enroll or not to 
enroll, understood the benefits and risks of enrolling their infants into the PENUT Trial. 
Many surveyed parents reported having enough support and advice to make a decision 
and did not feel pressure from others to make a decision. However, not all parents 
reported feeling sure about what to choose, and when asked if this decision was easy for 
them to make, only 10 of the 24 agreed to that statement. Overall, the majority felt that 
they made informed choices, they expected to stick with their choices, and they were 
satisfied or felt neutral about their decision to enroll or not to enroll their infants. 
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Table 10. Factors involved in parental decisions to enroll infants in PENUT (Part 1). 
Parents were asked to reflect on the choices they made when deciding whether or not to 
enroll their infants in the PENUT Trial.   
N=24 (6 not reported) Strongly 
Agree 
Agree Neither Agree 
nor Disagree 
Disagree Strongly 
Disagree 
I knew which choices were available to me. 3 18 2 1 0 
I knew the benefits of each choice. 0 18 4 2 0 
I knew the risks of each choice. 1 18 4 1 0 
I was clear about which benefits mattered most to 
me. 
1 20 3 0 0 
I was clear about which risks mattered most. 1 20 3 0 0 
I was clear about which was more important to 
me (benefits or risks). 
1 20 3 0 0 
I had enough support from others to make a 
choice. (“Others” could be family, medical 
providers, etc.) 
5 17 1 1 0 
I chose without pressure from others. 4 17 3 0 0 
I had enough advice to make a choice. 1 21 1 1 0 
I was clear about the best choice for my baby. 2 19 2 1 0 
I felt sure about what to choose. 3 13 6 2 0 
This decision was easy for me. 0 10 5 6 3 
I feel that I made an informed choice. 2 20 2 0 0 
I expected to stick with my choice. 2 18 3 1 0 
My decision showed what was important to me at 
the time. 
2 19 2 1 0 
I am satisfied with my decision. 3 15 6 0 0 
 
When asked how important several factors (listed in Table 11) were to the parents 
when deciding whether or not to enroll their infants into the PENUT Trial, most parents 
reported that the possible contribution to science and medicine, the potential benefit to 
future premature infants, the possible risks associated with the study drug Epo, and the 
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thought of their children being experimented on were “important” factors. However, what 
most parents considered to be “very important” was the potential benefit to their children.  
 
Table 11. Factors involved in parental decisions to enroll infants in PENUT (Part 2). 
Consenting parents were asked to gauge the importance of several factors when providing 
consent for baby to enroll in PENUT Trial.  
  
As listed in Table 12, most parents agreed that they had enough time to make their 
decisions to enroll infants into the PENUT Trial, despite the fact that the window of 
opportunity to enroll infants is 24 hours after the baby is born. An equal number of 
parents agreed and disagreed that being overwhelmed affected their willingness to hear 
about the study and that being asked to enroll their children in the study added to their 
worries at the time. The majority of surveyed parents trusted that doctors and researchers 
put the child’s well-being before the needs of the research study. They realized that a 
doctor does not have to do what the research study says if it means harming the baby. 
 
 
 
N=21 (9 not reported) Very 
Important 
Important Neutral Somewhat 
Important 
Not at all 
Important 
The possible contribution to science and 
medicine.  
3 9 4 3 2 
The potential benefit to my child. 14 6 0 0 1 
The potential benefit to future premature infants.  9 10 0 0 2 
The possible risks associated with Epo. 6 11 2 0 2 
The thought of my child being experimented on. 4 9 4 3 1 
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Table 12. Factors involved in parental decisions to enroll infants in PENUT (Part 3). 
Parents were asked to agree or disagree to several statements gauging how they felt when 
deciding to consent their infants in the PENUT Trial. 
 
The majority of parents who enrolled their infants into the PENUT Trial agreed 
that some of their hopes for enrolling their infants into PENUT included that their child 
would have a better future, that other preterm infants would have better futures, and that 
participating in a study would improve care for their child (Table 13). 
 
 
 
 
 
 
N=24 (6 not reported) Strongly 
Agree 
Agree Neither 
Agree nor 
Disagree 
Disagree Strongly 
Disagree 
I had enough time to make my decision to 
participate in the PENUT trial. 
1 11 4 6 2 
Having the opportunity to participate in this 
study reduced some of my fears for my child.  
1 12 9 2 0 
My feelings of being overwhelmed by the 
delivery of an extremely preterm infant affected 
my willingness to hear about the PENUT trial. 
5 7 4 8 0 
Being asked to have my child participate in the 
PENUT trial added to my worries at the time.  
3 8 4 9 0 
I trust the doctors and researchers to put my 
child’s well-being before the needs of the 
research study. 
1 16 6 1 0 
A doctor has to do what the research study says 
even if it is harmful to the baby s/he is caring for. 
0 2 5 15 2 
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Table 13. Factors involved in parental decisions to enroll infants in PENUT (Part 4). 
Consenting parents were asked to reflect on what some of their hopes were for enrolling 
their infants in the PENUT Trial.  
N=20 (10 not reported) Strongly 
Agree 
Agree Neither 
Agree nor 
Disagree 
Disagree Strongly 
Disagree 
My child would have a better future. 
 
6 13 1 0 0 
Other premature infants would have a better 
future. 
 
3 14 3 0 0 
Participating in a study would improve care for 
my child. 
4 11 5 0 0 
 
Parental knowledge and understanding of the PENUT Trial 
The last series of questions in the ethics survey consisted of 10 statements that 
parents had to identify as being true or false (Table 14). Ideally, parents were approached 
to complete this survey when the infants were between days of life 15 and 43. However, 
for purposes of this research thesis, some of the responding parents were surveyed 
outside of this window (some of them were surveyed when their infants were almost two 
years old). To accommodate a potentially large gap between when parents were surveyed, 
an option of “unsure” was given to parents when they were not certain about the validity 
of the true or false statements. 
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Table 14. Parental understanding of the PENUT Trial. Parents were asked to respond 
to 10 true or false statements regarding the PENUT Trial. Highlighted responses are 
correct. 
 
As seen in Table 14, the majority of parents responded correctly to some of the 
statements. Overall, 77.3% of parents knew that: (1) not all enrolled PENUT infants 
receive Epo—half receive the study drug and half receive the placebo/saline solution, (2) 
infants born before 28 weeks are at higher risk of developing long-term growth and 
development problems, and (3) the goal of the PENUT Trial is to find out if Epo can 
protect premature infants from having neurologic problems. Furthermore, 86.4% of 
parents pointed out that participating in the PENUT Trial was entirely voluntary.  
For some statements, parents did not respond as accurately. Only 50% correctly 
replied that infants in the PENUT Trial may get more blood draws. Similarly, only 54.5% 
N=22 (8 not reported) True False Unsure 
All children enrolled in PENUT would receive Epo. 1 17 4 
Epo is approved by the US Food and Drug Administration (FDA) to increase red 
blood cell production in adults. 
8 4 10 
Epo is approved by the FDA for use in premature infants. 11 1 10 
Infants born before 28 weeks are at high risk of developing long-term problems 
with growth and development.  
17 1 4 
Goal of PENUT Trial is to find out if Epo can protect premature infants from 
having neurologic problems. 
17 1 4 
Goal of PENUT trial is to find out if higher dose of Epo is safe for premature 
infants. 
7 5 10 
Participation in the PENUT trial was voluntary. 19 0 3 
Infants in the PENUT trial may get more shots. 7 7 8 
Infants in the PENUT trial may get fewer blood draws. 2 11 9 
Infants in the PENUT trial may get more blood transfusions. 0 12 10 
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correctly chose false to the statement that “infants in the PENUT Trial may get more 
blood transfusions.” Moreover, only 31.8% knew that PENUT infants may get more 
shots because the low dose of the study drug is given subcutaneously.  
Only 36.4% of responding parents were aware that Epo is in fact approved by the 
U.S. Food and Drug Administration (FDA) to increase red blood cell production in 
adults. An even fewer number of parents (31.8%) knew that one of the goals of the 
PENUT Trial is to discover if the higher dose of Epo is safe for premature infants. Also, 
only 1 parent out of all of the responding parents (3.3%) knew that Epo is not yet 
approved by the FDA for use in premature infants—which is the main reason for this 
study, to determine if Epo has neuroprotective effects and to seek FDA approval for use 
in preterm infants. 
 
Parental overall experience during consent process for PENUT Trial 
At the end of the survey, parents were asked to rate (1 = poor, 5 = excellent) their 
overall experiences during the consent process of the PENUT Trial (Table 15). Whereas 
the average rating among non-consenters was 2.75, the average rating among consenters 
was 4.00. Overall, the average rating was 3.77. Although the overall rating was above 
average, there is still room for improvement for parental experience when being 
approached for the PENUT Trial. The discussion section will outline different ways in 
which the research study staff may improve the experience of parents being asked to 
enroll their extremely preterm infants into a clinical trial. 
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Table 15. Parental rating of overall experience with consent process.  
 Consenters (n=22) Non-Consenters (n=8) Total (n=30) 
Overall, how would you rate your 
experience in being asked to join the 
PENUT Trial? 
   
1 (poor) 0 0 0 
2 1 2 3 
3  4 1 5 
4 7 1 8 
5 (excellent)  6 0 6 
Not reported 4 4 8 
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DISCUSSION 
 
Description of demographic factors of parents responding to PENUT ethics survey 
Comparing the demographic characteristics of parents who consented to the 
PENUT Trial with parents who did not consent to the PENUT Trial was difficult because 
of the very small sample size of parents surveyed. Furthermore, the number of consenting 
parents approached for the ethics survey (n = 22) was almost three times greater than the 
number of non-consenting parents approached for the survey (n = 8). Despite the small 
sample size, some results may be noteworthy.  
The analysis of parental education levels showed that roughly equal numbers of 
mothers and fathers reported having college degrees. However, several mothers reported 
having graduate degrees, whereas none of the fathers reported having any graduate 
school experience. Although it was more difficult to attain paternal education level than 
maternal education level, the results indicated that the majority of the mothers 
approached for the ethics survey had formal and higher level education.  
Another noteworthy result was that most parents had private health insurance. 
Since the PENUT Trial recruited patients at Harvard Medical School teaching hospitals, 
it was not unexpected that most parents had private health insurance.  
One suggestion for future studies is to diversify the socioeconomic background 
and health insurance status of families by recruiting patients from hospitals that treat 
patients who are insured as well as uninsured and who come from households with lower 
income levels and less prevalence of higher education among parents. Because the 
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PENUT Trial and ethics survey are being conducted nationwide, the results of the entire 
study are expected to be more diverse than the preliminary findings of this research thesis 
and will allow comparison of responses based on socioeconomic status. 
 
Interpretation of feedback from parents responding to PENUT ethics survey 
Overall, the feedback received from parents who completed the PENUT Trial 
ethics survey provided researchers with insight into which aspects of the consenting 
process can be improved upon. There was a general consensus that mothers would have 
preferred to be approached before their infants were born, confirming the hypothesis of 
this research thesis. The prenatal period was the time most mothers described themselves 
as being calmer and having more time to consider the risks and benefits of the study. Of 
the eight non-consenting mothers, only one of them had been approached prenatally. This 
may suggest that although approaching parents before the baby is born will not 
necessarily guarantee they will enroll their infants in the PENUT Trial, approaching 
parents after the baby is born may make parents less likely to enroll their infants in the 
PENUT Trial.  
 Many mothers did not have strong preferences about who should approach them 
concerning the PENUT Trial, but some surveyed mothers reported that they preferred to 
be approached by the baby’s neonatologist rather than a doctor not involved in the baby’s 
care. These mothers felt that the baby’s doctor has the baby’s best interest in mind and 
would provide good advice regarding whether or not to enroll the baby into the PENUT 
Trial. Although several mothers preferred that the baby’s doctor approach them about the 
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study, they also wanted to be approached by someone involved in the study itself. 
Currently, three neonatologists and two research study coordinators are actively involved 
in enrollment for the PENUT Trial. Two other neonatologists assist with parental consent 
and enrollment. The feedback from surveyed mothers suggested that either (1) the doctor 
involved in care for the baby should also be involved in the PENUT Trial or (2) the 
baby’s neonatologist and a second doctor involved in the PENUT Trial should together 
approach the mother to discuss the study. Based on this feedback, one recommendation is 
to increase the number of neonatologists who are knowledgeable about the PENUT Trial 
and are able to approach and consent parents to enroll their infants into the PENUT Trial. 
 
Strengths and limitations of PENUT ethics survey and research thesis  
The strengths of the PENUT ethics survey and additional questionnaire were: 
 Feedback from both consenting and non-consenting parents of the PENUT 
Trial provided valuable insight on consent process.  
 Commentary from the parents responding to the survey provided more 
personal and detailed feedback for study investigators about consent process. 
 Structure gave unique perspective because not many studies focus on parental 
consent experience. 
The limitations of the PENUT ethics survey and additional questionnaire were:  
 Small sample size prevented statistical analysis from being done. 
 Fewer non-consenting parents were surveyed than consenting parents.  
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 Not all surveyed parents provided feedback to all sections of the 
questionnaire. 
 Surveyed parents lacked diversity regarding socioeconomic status, household 
income levels, and education levels.  
 
Steps to improve parental consent process in future research trials involving neonates 
Giving birth to an extremely preterm infant is an emotional and stressful event for 
parents, and providing consent to enroll extremely preterm infants into a research trial is 
a challenging task for most parents. The role of the research study staff is to provide 
parents with ample time, support, information, and guidance to help them make informed 
decisions. As suggested by Ballard et al. (2004), involving parents in the consent process 
and explaining the risks and benefits of the study are very important. It is also crucial that 
study staff explain the voluntary nature of clinical research trials and ensure that consent 
forms are accurate, easy to understand, and up-to-date. As stated by Drazen et al. (2015), 
it is important for researchers to be as thorough and informative in verbal discussion of 
the study and on paper with the signed informed consent form.  
Ethics surveys conducted while a research study is ongoing, as seen with the 
PENUT Trial, are effective because they provide study investigators with almost 
immediate feedback on how to improve upon the parental consent and enrollment 
process. Although the number of surveyed parents for purposes of this research thesis 
was only a small subset of the nationwide ethics survey that seeks to survey 300 parents 
by summer 2016, the feedback from consenting and non-consenting parents has already 
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helped study staff at BIDMC to identify areas for improvement when approaching 
parents and seeking consent for enrollment of their extremely preterm infants into the 
PENUT Trial.  
Although enrollment for the PENUT Trial at BIDMC and nationwide is over 80% 
of the target goal, the investigators at BIDMC plan to spend the remaining few months 
making the following adjustments to the parental consent and enrollment process:  
 Increase screening of antepartum, and labor and delivery floors for 
pregnant mothers who are within the window for the PENUT Trial. 
 Approach mothers prenatally whenever possible, and reserve postnatal 
approach and consent only for mothers who are not available for approach 
before delivery. 
 Reach out to more obstetrician/gynecologists (OB/GYNs) and 
neonatologists at BIDMC to become involved in the PENUT Trial so 
mothers have options to consult with their doctor or the baby’s doctor. 
 Conduct ethics surveys to receive parental feedback whenever possible. 
In summary, conducting ethics surveys with all parents approached for research 
studies involving neonates is a very useful tool for study investigators to improve the 
consent process for current and future studies.   
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APPENDIX 
Appendix 1. PENUT Trial ethics survey  
 
We are doing a survey of parents who were told about the PENUT trial, a research 
study to learn whether a drug called erythropoietin (Epo) might affect the long-term 
outcomes of premature babies. You were offered the choice to have your baby 
participate in the trial. This survey is to understand more about that experience. It 
should take approximately 15 minutes. Please answer all questions to the best of 
your ability. The survey is voluntary and you can stop at any time. 
Thank you in advance for agreeing to take this survey.  
 
1. Did you give permission for your baby to participate in the PENUT Trial? 
Yes    No 
 
2. Did you listen to the PENUT study description (study background, risks, benefits, 
etc) before making a decision? 
Yes    No 
 
The next series of questions are about your experience first learning about the 
PENUT trial.   
3. When were you first approached about the PENUT trial? 
Before the baby was born   After the baby was born 
 
4. Who first approached you to ask about participating in the PENUT Trial? 
a. A doctor caring for your baby (your neonatologist) 
b. A doctor NOT caring for your baby (NOT your neonatologist) 
c. A Study Coordinator 
d. Unsure 
 
5. Was this person involved in the PENUT Trial? 
a. Yes 
b. No 
c. Unsure 
 
6. Did you talk to that person more than once before deciding? 
Yes (Number or times _____)  No, just once 
 
7. Over what time period did you talk to this person before deciding? 
Hours   Days   Weeks   
 
 
 59 
8. Did you talk to anyone else before making your decision? 
Yes    No 
 
If yes, whom? (Check all that apply) 
a. Your partner 
b. Nurse  
c. Another Doctor (OB or Neonatologist)  
d. Research Coordinator 
e. Family Member  (mother’s mother, father’s mother, friend, father of the 
baby, partner, etc)  
f. Other  
 
9. I generally trusted the person who talked to me about the PENUT trial.  
1  2  3  4  5 
Did not Trust at all      Trusted Completely  
 
The next series of questions are about signing the permission document allowing 
your child to participate in the PENUT study. 
10. When did you first sign the permission form? 
Before the baby was born    After the baby was born 
 
11. At the time you signed the permission document, was the person who acquired this 
consent the same person who had approached you the first time? 
Yes    No   Unsure 
 
IF NO OR UNSURE PLEASE ANSWER THE FOLLOWING (BRANCHING LOGIC 
BUILT IN): 
 
12. Who asked you to sign the permission document for the PENUT trial?  
a. A doctor caring for your baby (your neonatologist) 
b. A doctor NOT caring for your baby (NOT your neonatologist) 
c. A Study Coordinator 
d. Unsure 
 
13. Was that person involved in the PENUT trial?  
a. Yes 
b. No 
c. Unsure 
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Please think back to the time before your baby was born, and their first day of life. 
The PENUT trial team asked for your permission before (BRANCHING LOGIC: or 
after) your baby was born 
 
14. Now imagine that you had been asked for permission after your baby was born.  Do 
you think that would have felt _______________ than asking before your baby was 
born (as you did).  
1  2  3  4  5 
Less Stressful   No Difference   More Stressful 
 
OR 
 
15. Now imagine that you had been asked to consent before your baby was born. Do you 
think that would have felt ______________________ than asking after your baby 
was born (as you did).  
1  2  3  4  5 
Less Stressful   No Difference   More Stressful 
 
If you would like to say more about your answer, write it below: 
 
16. Please reflect on your choice to participate in the PENUT trial. We would like to ask 
you some questions about that choice. 
 
 Strongly 
Agree 
Agree Neither 
Agree 
nor 
Disagree 
Disagree Strongly 
Disagree 
I knew which choices were 
available to me. 
     
I knew the benefits of each 
choice. 
     
I knew the risks of each 
choice. 
     
I was clear about which 
benefits mattered most to me. 
     
I was clear about which risks 
mattered most. 
     
I was clear about which was 
more important to me 
(benefits or the risks). 
     
I had enough support from 
others to make a choice. 
(“Others” could be family, 
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17. Who would you MOST prefer ask for your permission for your baby to participate in 
a research trial? 
a. Your OB 
b. Your baby’s doctor  
c. Another Doctor not responsible for the care of my baby  
d. A research study coordinator  
 
18. Would you prefer if that person was ____________ ? 
a. Involved in the research trial 
b. NOT involved in the research trial 
 
19. Who would you LEAST prefer ask for your permission for your baby to participate in 
a research trial? 
a. Your OB 
b. Your baby’s doctor  
c. Another Doctor not responsible for the care of my baby 
d. A research study coordinator  
 
Why?  
 
 
 
medical providers, etc) 
I chose without pressure 
from others. 
     
I had enough advice to make 
a choice. 
     
I was clear about the best 
choice for my baby. 
     
I felt sure about what to 
choose. 
     
This decision was easy for 
me. 
     
I feel that I made an 
informed choice. 
     
I expected to stick with my 
choice. 
     
My decision showed what 
was important to me at the 
time. 
     
I am satisfied with my 
decision. 
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20. When would you prefer that this person ask your permission? 
a) Before the baby is born 
b) After the baby is born 
c) Other ______________________ 
Why?   
 
21. How important were the following factors in making your decision to enroll your 
baby in the PENUT Trial? 
 
 
22. Please indicate if you agree or disagree with the following statements. 
 Very 
Important 
Important Neutral Somewhat 
Important 
Not at all 
Important 
The possible 
contribution to science 
and medicine.  
     
The potential benefit to 
my child. 
     
The potential benefit to 
future premature 
babies.  
     
The possible risks 
associated with Epo. 
     
The thought of my 
child being 
experimented on. 
     
 Strongly 
Agree 
Agree Neither 
Agree 
nor 
Disagree 
Disagree Strongly 
Disagree 
I had enough time to make 
my decision to participate the 
PENUT trial. 
     
Having the opportunity to 
participate in this study 
reduced some of my fears for 
my child.  
     
My feelings of being 
overwhelmed by the delivery 
of an extremely preterm 
infant affected my willingness 
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23. What did you hope would happen as a result of enrolling in the study?  
 
 Strongly 
Agree 
Agree Neither 
Agree or 
Disagree 
Disagree Strongly 
Disagree 
My child would have a better 
future. 
 
     
Other premature babies would 
have a better future. 
 
     
Participating in a study would 
improve care for my child. 
     
 
 
24. The following questions are about your understanding of the PENUT trial based on 
what we told you. This will measure our team’s ability to explain the study to you 
(ANSWERS WILL BE REMOVED) 
to hear about the PENUT 
trial. 
Being asked to have my child 
participate in the PENUT trial 
added to my worries at the 
time.  
     
 
I trust the doctors and 
researchers to put my child’s 
well-being before the needs 
of the research study.  
     
A doctor has to do what the 
research study says even if it 
is harmful to the baby she is 
caring for. 
     
 True False Unsure 
All children enrolled in PENUT would receive Epo. 
 
 Correct  
Epo is approved by the US Food and Drug 
Administration (FDA) to increase red blood cell 
production in adults. 
Correct   
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25. Overall, how would you rate your experience in being asked to join the PENUT Trial: 
 
1  2  3  4  5 
Poor       Excellent 
 
 
26. I would give permission to have my child participate in a research study in the future. 
 
Yes   No   Maybe 
 
27. Please tell us about what you liked or disliked about your experience in being asked 
to join the PENUT trial?   
 
28. Please say more about the main reasons you chose to participate or not participate in 
the PENUT study.   
 
 
 
 
 
Epo is approved by the FDA for use in premature 
infants. 
 
 Correct  
Infants born before 28 weeks are at high risk of 
developing long-term problems with growth and 
development.  
 
Correct   
The goal of the PENUT Trial is to find out if Epo can 
protect premature infants from having neurologic 
problems. 
 
Correct   
The goal of the PENUT trial is to find out if the higher 
dose of Epo is safe for premature infants. 
 
Correct   
Participation in the PENUT trial was voluntary. 
 
Correct   
Babies in the PENUT trial may get more shots. 
 
Correct   
Babies in the PENUT trial may get fewer blood draws.  Correct  
Babies in the PENUT trial may get more blood 
transfusions. 
 Correct  
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Demographics 
 
29. What is your gender?  
Male  Female 
 
30. What is your age?  ____________ 
 
31. What is your relationship to the baby? 
Mother Father  Guardian  Other ______________ 
 
32. What is your highest level of education? 
some high school 
high school graduate/GED 
some college 
college graduate 
some graduate school 
graduate degree 
 
33. What was your household's total income last year before taxes? 
$30,000 or less     >$30,000 - $55,000 >$55,000 - $95,000       >$95,000 
 
34. Have you or a close relative (parents, sibling, or child) or friend who has ever 
participated in a research trial before?     
Yes  No  Don’t know 
 
35. What was the Gestational Age of your child at birth? 
24 weeks  25 weeks  26 weeks  27 weeks 
 
 
36. With which race do you best identify? 
Black or African-American   Asian     
White or Caucasian    American Indian or Alaska Native  
Native Hawaiian or other Pacific Islander Other  
 
37. How important is religion or spirituality in your life? 
Very Important   Important   
Somewhat Important  Not at all Important  
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Appendix 2. Additional Questionnaire 
Additional questions for whoever is responding to survey: 
1. What is your home zip code? (note: your zip code will not be used in data analysis, it 
is simply to measure how far your home zip code is from BIDMC) _____________  
 
2. How do you commute to the hospital? 
Private Car  Carpool/Vanpool Public Transportation/MBTA  
Taxi/Uber/Lyft Other _______________ 
 
3. How many hours, on average, do you spend in the NICU with your baby every day? 
<1 1-2  3-4 5-6 7+ 
 
4. Including this child, how many other children live with you? 
1 2 3 4 5 6 7+ 
 
5. Health insurance name: ___________________ 
 
6. Health insurance type:  
Mass Health  Medicaid Other Public Insurance  
HMO   PPO  Other Private Insurance  
No insurance  Unknown Other____________ 
 
Additional demographics information: 
7. Mother’s age: __________ 
 
8. Father/Partner’s age: ___________ 
 
9. Mother’s highest level of education? 
Some high school 
High school graduate/GED 
Some college 
College graduate 
Some graduate school 
Graduate degree 
 
10. Father/Partner’s highest level of education? 
Some high school 
High school graduate/GED 
Some college 
College graduate 
Some graduate school 
Graduate degree 
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11. Mother’s occupation: _________________________ 
 
12. Father/Partner’s occupation: __________________________ 
 
13. Mother’s ethnicity:  
Hispanic or Latino Not Hispanic or Latino   
Unknown  Not Reported 
 
14. Father/Partner’s ethnicity:  
Hispanic or Latino Not Hispanic or Latino   
Unknown  Not Reported 
 
15. Mother’s race: 
Black or African-American  Asian  White or Caucasian  
American Indian or Alaska Native Native Hawaiian or other Pacific Islander  
Other 
 
16. Father/Partner’s race: 
Black or African-American  Asian  White or Caucasian  
American Indian or Alaska Native Native Hawaiian or other Pacific Islander  
Other 
 
17. Primary language spoken at home:  
English Spanish Chinese Tagalog 
French  Vietnamese German Korean 
Unknown Other _______________ 
 
18. Secondary language spoken at home: 
English Spanish Chinese Tagalog 
French  Vietnamese German Korean 
Unknown Other _______________ 
 
19. Does mother need a translator? 
Yes  No 
 
20. Marital status:  
Never Married  Married Domestic Partnership  Separated 
Divorced  Widowed Not Reported 
 
21. What is your religious affiliation?  
Catholic Jewish  Protestant 
Other religion—includes Buddhist, Hindu, Mormon, Muslim, Eastern Orthodox, 
and Other 
None—includes Atheist, Agnostic, and None 
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